Sort   by:  
 Page size 
ProteomicsSerum proteomic profile of asthmatic patients after 6 months of Benralizumab and Mepolizumab treatment
Severe eosinophilic asthma is characterized by chronic airway inflammation, oxidative stress and elevated proinflammatory cytokines, especially IL-5. Mepolizumab and benralizumab are both humanized IgG antibodies directed against IL-5 signaling, directly acting on eosinophils count. Together with th...
ORGANISM(S): Homo sapiens (Human) 
2022-04-01 | PXD029793 | Pride
Apoc Severe eosinophilic asthma. Mepolizumab  benralizumab  ceruloplasmin  plasminogen  apoa1 
GenomicsGene signature profiles in whole blood cells from severe asthma patinets treated with benralizumab
Gene signature profiles in whole blood cells from severe asthma patinets treated with benralizumab
PRJNA625496 | ENA
TranscriptomicsGene signature profiles in whole blood cells from severe asthma patinets treated with benralizumab
Severe asthma is a clinically and physiologically heterogeneous disease. Benralizumab is a monoclonal antibody which binds the alpha chain of the interleukin-5 receptor and used for severe eosinophilic asthma worldwide. However, not all eosinophilic asthma patients will benefit from benralizumab due...
ORGANISM(S): Homo sapiens 
2023-04-15 | GSE148725 | GEO
ClinicalEfficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still symptomatic despite standar...
2263424 | ecrin-mdr-crc
TranscriptomicsBenralizumab treatment in patients with severe asthma: A comparative analysis of T-cell gene expression profiles and identification of response-associated genes
Benralizumab, an antibody that targets the interleukin-5 (IL-5) receptor, suppresses IL-5 activity, which plays a critical role in eosinophil development. Clinical studies have shown its efficacy in reducing eosinophil counts in both the blood and sputum, which has been shown to be beneficial for pa...
ORGANISM(S): Homo sapiens 
2025-06-10 | GSE290782 | GEO
GenomicsBenralizumab treatment in patients with severe asthma: A comparative analysis of T-cell gene expression profiles and identification of response-associated genes
Benralizumab treatment in patients with severe asthma: A comparative analysis of T-cell gene expression profiles and identification of response-associated genes
PRJNA1230105 | ENA
GenomicsBacteria
Characterising the microbiome in COPD sputum treated with benralizumab
PRJNA1114681 | ENA
UnknownEffect of benralizumab treatment on the airway microbiome in COPD.
Not available
S-EPMC11973710 | biostudies-literature
UnknownEffects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Not available
S-EPMC4172321 | biostudies-literature
UnknownPerspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Not available
S-EPMC8960447 | biostudies-literature
Sort   by:  
 Page size